Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents.

@article{Hochster2003NewerAT,
  title={Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents.},
  author={Howard S. Hochster},
  journal={International journal of radiation oncology, biology, physics},
  year={2003},
  volume={56 4 Suppl},
  pages={24-30}
}
To review the use of gemcitabine-based therapy in pancreatic cancer, including fixed-dose-rate (FDR) infusion and novel combinations. On the basis of pharmacokinetic data, studies have been performed using an FDR of gemcitabine of 10 mg/m(2)/min in an effort to maintain a critical plasma concentration of gemcitabine, and thus increase tumor cytotoxicity and therapeutic efficacy. The dose-limiting toxicities in Phase I studies were mucositis and myelosuppression. A multicenter Phase II study… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…